A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC
The five-year survival rate for people diagnosed with the most advanced stage of non-small cell lung cancer (NSCLC) is between one and 10 percent.
To address this devastating condition, UCLA researchers are genetically modifying a patient’s own dendritic cells – key cells of the immune system – to boost their ability to stimulate native T cells - a type of white blood cell - to destroy cancer cells.
The investigators will combine this cell therapy with the FDA-approved therapy pembrolizumab (better known as Keytruda) a therapeutic that renders cancer cells more susceptible to clearance by the immune system.
Dose escalation and expansion.
Determination of maximum tolerated dose and objective response rate at selected dose in lung cancers.